GEN Exclusives

More »

GEN News Highlights

More »
Jan 4, 2007

Roche and Synosis Form CNS Partnership

  • Synosis Therapeutics acquired five drug candidates targeting the central nervous system from Roche. Of the five Roche-discontinued compounds are Phase I molecules. "By partnering with Synosis, we're giving these potential medicines the best chance of success by creatively extending our innovation base in an important therapeutic area," comments Peter Hug, Roche's global head of Pharma Partnering.

    Under the terms of the deal, Synosis will be responsible for the clinical development of all five candidates. Roche retains the right to opt-in to two preselected programs. Synosis has full commercial rights to three preselected programs.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Companion Animal Care

Do you think Americans spend too much on companion animal care?